Chordate Medical’s CEO, Anders Weilandt, will present Ozilia at Swiss Nordic Bio in Zurich on March 7th. Swiss Nordic Bio is a high-level partnering and investor conference aimed at connecting Nordic and Swiss startups in the Life Science sector with investors and industry partners.
“As we continue to penetrate key markets, we will increasingly focus on raising awareness about the company and Ozilia within the industrial and investor circles surrounding Life Science. Swiss Nordic Bio is one of several important forums in this context during the spring where we participate to present Ozilia’s potential,” said Anders Weilandt, CEO of Chordate.
Swiss Nordic Bio has been held for 17 years and was previously known as the Swiss Scandinavian Bio-Business Seminar. The conference is hosted by Vator Securities and Business Sweden and organized together with stakeholders from the Nordic countries in collaboration with Swiss partners.
“The conference focuses on biotechnology, medtech, and the pharmaceutical industry. In addition to development companies like Chordate and investors, global companies from these three fields also participate, making this the perfect forum for us to be a part of.”